What happens when your biopsy results come back
A prostate biopsy is usually ordered after a PSA (prostate-specific antigen) blood test returns an elevated result, or after a digital rectal exam finds an area of concern. During the procedure, a urologist removes small tissue samples from several areas of the prostate. A pathologist examines those samples under a microscope and writes a pathology report. That report arrives with numbers and terms that are often unfamiliar. The Gleason score is the most important of those numbers.
This guide explains what each part of your biopsy report is measuring, how the Gleason score and Grade Group are assigned, and what published research shows for integrative support in the period following diagnosis. All supplement options described here should be discussed with your oncologist before use.
How the Gleason score is calculated
The Gleason score describes how different the cancer cells look from normal prostate tissue under a microscope. When cells look very different from healthy tissue, they are described as high grade. High-grade cells tend to grow and spread more quickly than low-grade cells. The Gleason system captures this difference in a number between 6 and 10 – the practical range used in modern pathology.
A pathologist identifies the two most common cell patterns in your sample. Each pattern receives a grade from 1 to 5. Those two grades are added together to form the Gleason score. Mayo Clinic explains that a result written as 3 + 4 = 7 means the largest area of cancer showed grade 3 cells and the second largest area showed grade 4 cells. A result of 4 + 3 = 7 uses the same numbers in reverse. The order matters: a 4 + 3 pattern generally carries a higher risk than 3 + 4 because more of the sampled tissue showed the more aggressive pattern, even though both scores sum to 7.
Gleason score and Grade Group: a comparison
| Feature | Grade Group 1 | Grade Group 2-3 | Grade Group 4-5 |
|---|---|---|---|
| Gleason score equivalent | Gleason 6 (3+3) | Gleason 7 (3+4 or 4+3) | Gleason 8-10 |
| Risk category | Low | Intermediate | High to very high |
| Active surveillance often discussed | Yes, in eligible men | Selected cases (Grade Group 2 more often) | Rarely recommended |
| Common management approaches | Monitoring or focal therapy | Surgery, radiation, or focal therapy | Surgery, radiation, hormone therapy, or combination |
Grade Group definitions per StatPearls on NCBI Bookshelf. Management approaches shown are general and vary by individual PSA level, extent of disease, and patient preference.
The Grade Group system
In 2016, a simplified five-level system called Grade Groups was introduced alongside the Gleason score. Grade Groups run from 1 (least aggressive) to 5 (most aggressive). As described in StatPearls on NCBI Bookshelf, the system was adopted partly to reduce patient confusion. Many people found it unsettling to hear that their cancer was a Gleason 6 when the scale nominally ran to 10. Calling it Grade Group 1 makes clearer that it represents the lowest risk level in current clinical practice. Your pathology report may show both numbers. They refer to the same finding and describe the same tissue.
Other information on your pathology report
The Gleason score is not the only number that matters. Your report will include several additional data points. The American Cancer Society guide to prostate pathology reports describes the following as commonly included:
- Number of cores taken and cores positive for cancer. A standard biopsy typically removes 10 to 12 tissue samples from different zones of the prostate. Fewer positive cores generally indicates less extensive disease. Each positive core may also report what percentage of that sample contains cancer cells.
- Perineural invasion. This indicates whether cancer cells were found near nerve fibers inside the prostate. It does not automatically change treatment decisions, but your oncologist will weigh it alongside other findings.
- Extraprostatic extension. If cancer cells appear to have grown through the outer layer of the prostate into surrounding tissue, this is noted and affects staging and treatment planning.
- Seminal vesicle involvement. Cancer reaching the seminal vesicles signals more advanced local spread and shifts staging upward.
- Lymphovascular invasion. Presence of cancer cells in small lymph or blood vessels within the biopsy tissue is another factor your care team will review when planning next steps.
PSA levels, staging, and risk groups
PSA is a protein produced by both normal and cancerous prostate cells. A single elevated PSA value does not diagnose cancer on its own. After a biopsy confirms cancer, your oncologist uses your PSA level together with the Gleason score and tumor stage (T-stage) to assign a risk group. The T-stage describes how far the tumor extends within or beyond the prostate gland itself.
The combination of PSA level, Grade Group, and T-stage drives most initial treatment discussions. The American Cancer Society staging overview describes how oncologists place men into low, intermediate (favorable or unfavorable), high, and very high risk groups. These categories shape which management options are appropriate and what treatment steps your doctor may recommend.
For men with Grade Group 1 disease and a PSA below 10 ng/mL, active surveillance – structured monitoring without immediate treatment – is an evidence-supported option recognized by several major clinical guidelines. If you are in this category, you may find it useful to read Active Surveillance vs. Treatment in Prostate Cancer, which covers the monitoring criteria doctors use in practice and what typically triggers a shift to active treatment.
For men with Grade Group 4 or 5 disease, treatment is usually needed without delay. Hormone therapy (androgen deprivation therapy, or ADT) is often part of treatment for high-risk disease. ADT carries downstream effects on metabolic health, body weight, and hormonal balance that are worth planning for early in the process. The companion article Estrogen Rebalancing After Prostate Cancer ADT covers one of those longer-term considerations in detail.
Integrative support: what the published research shows
Many men look for evidence-based integrative options to use alongside conventional treatment. The compounds below have been studied in prostate cancer contexts. The evidence base for all of them is early – most studies are laboratory or animal research, and large randomised controlled trials in human prostate cancer populations are limited. None of these compounds replace surgery, radiation, or hormone therapy. Always discuss each option with your oncologist before adding it to your routine.
Curcumin
Curcumin is the active polyphenol found in turmeric. A 2020 review published in Nutrients (PMC7696488) found that curcumin has shown antiproliferative and pro-apoptotic activity in prostate cancer cell lines across multiple laboratory studies. One small clinical study referenced in the review tested curcumin combined with isoflavones in men with elevated PSA and found a reduction in PSA levels in the curcumin group. This is a small, early study and does not establish curcumin as a treatment for prostate cancer.
Cancer Research UK notes that standard curcumin is poorly absorbed in the gut, making absorption a major challenge for any clinical application. Formulations that use a BCM-95 matrix – a blend of curcuminoids and turmeric essential oil – help improve absorption compared to standard powdered extracts. Doses studied across the cited prostate cancer research varied considerably, and you and your clinician should decide on the right dose for you, not one you pick on your own.
Berberine
Berberine is a plant-derived alkaloid that has been studied for its effects on androgen signalling in prostate cancer. A study published in Cancer Biology and Therapy (PMC4955188) found that berberine inhibited the enzyme aldo-keto reductase 1C3 (AKR1C3) in castration-resistant prostate cancer cell lines. AKR1C3 is involved in local androgen synthesis, one mechanism by which cancer can continue to grow after initial hormone therapy. A separate study in Molecular Medicine Reports (PMC3154574) found that berberine suppressed androgen receptor signalling in prostate cancer cells. Both studies are laboratory research, not human clinical trials.
For men whose oncologist considers berberine a suitable integrative addition, Oncostore’s Berberine Daily 500 provides a standardised 500 mg dose per serving. Berberine at this dose interacts with multiple prescription medications – including metformin, certain antibiotics, and anticoagulants – so disclose it to your full care team before starting.
Green tea extract (EGCG)
Epigallocatechin gallate (EGCG) is the primary active catechin in green tea. Laboratory studies have found EGCG may influence prostate cancer cell growth in multiple ways, including effects on growth factor signalling and cell cycle regulation. Doses used in supplemental research have typically ranged from 400 mg to 800 mg EGCG per day, though human clinical trial data in prostate cancer is limited. Discuss timing and dosing with your oncologist before starting any active treatment.
Lifestyle approaches with supporting evidence
Diet, body weight, and physical activity are areas where the evidence base is more consistent, though largely observational. Large observational studies have linked plant-rich diets, healthy body weight, and lower risk of prostate cancer progression. Areas that come up most often in prostate cancer nutritional research include:
- Reducing saturated fat intake
- Increasing intake of cruciferous vegetables such as broccoli, cauliflower, and Brussels sprouts
- Limiting processed and red meat consumption
- Maintaining a healthy body weight
- Regular aerobic and resistance exercise, planned with your care team if bone health is already a concern
If your care plan includes or may include prostatectomy, start planning for post-surgical recovery before the procedure. The article Urinary Continence Recovery After Prostatectomy covers pelvic floor rehabilitation and realistic timeline expectations in detail.
Questions to raise at your next appointment
Your biopsy report starts a conversation that continues. Writing specific questions before your appointment helps you leave with a clearer picture. Consider asking:
- What is my Gleason score, Grade Group, and overall risk group?
- How many of my biopsy cores were positive, and what was the percentage cancer involvement in each?
- Is there any sign that cancer has grown beyond the prostate, and if so, how does that change my staging?
- Would imaging before treatment – such as MRI, bone scan, or PSMA PET scan – change the recommended plan?
- Am I a candidate for active surveillance, and what would trigger a move to active treatment?
- Which integrative supplements, if any, are safe to use alongside the treatment you are recommending?
Choosing quality formulations
If you and your oncologist agree that an integrative supplement is appropriate for your situation, formulation quality matters. Look for products that clearly state the specific extract used, the dose per serving, and the manufacturing standard. To explore the integrative oncology formulations Oncostore carries – including compounds that have been studied in cancer care contexts – visit the Integrative Oncology product category for current details and availability.
If you are on prescription medication, pregnant, or breastfeeding, speak with a clinician before adding any supplement to your routine.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
